<sub id="pfpd9"><dfn id="pfpd9"></dfn></sub>

<address id="pfpd9"><var id="pfpd9"></var></address>
<sub id="pfpd9"><var id="pfpd9"></var></sub>

<thead id="pfpd9"><var id="pfpd9"><ins id="pfpd9"></ins></var></thead>

<address id="pfpd9"><listing id="pfpd9"></listing></address>

<sub id="pfpd9"><dfn id="pfpd9"></dfn></sub>

<sub id="pfpd9"><dfn id="pfpd9"></dfn></sub>

    <thead id="pfpd9"><var id="pfpd9"><output id="pfpd9"></output></var></thead><sub id="pfpd9"><var id="pfpd9"><ins id="pfpd9"></ins></var></sub><sub id="pfpd9"></sub>
    <address id="pfpd9"></address><address id="pfpd9"></address>

    <sub id="pfpd9"><dfn id="pfpd9"></dfn></sub>

      Partnering

      Partnering plays a strategic role in executing our R&D strategy, evolving our portfolio and growth. Our goal in partnering is to discover, develop and deliver transformational medicines to patients by bringing innovative science, research and technology together with our capabilities and expertise.
      Paul Biondi

      Paul Biondi,?Senior Vice President, Strategy and Business Development

      "From our deep scientific experience, engaged senior leaders and transparent approach, we bring the best of Bristol-Myers Squibb to every opportunity and partnership."

      Why Competition in Deal Making is Good For Patients?

      By Paul Biondi, Senior Vice President & Head of Business Development
      Partnering to Speed: Transformational Medicines to Patients

      Partnering to Speed:?Transformational
      Medicines to Patients

      Combining passion, science and experience to deliver innovation together.


      Why Partner With Us

      With a long history of successful scientific and commercial collaborations that exhibit speed, collaboration, innovation, and strong partner relationships, research and development (R&D) is at the center of our strategy. With 41 compounds in development, a network of research facilities around the globe, and an annual R&D investment of $4.8 billion*,? we’ve been recognized as one of the premier R&D organizations in the industry.

      *This non-GAAP amount excludes significant upfront and milestone payments for business development transactions and other specified R&D items.?

      What We're Focused On

      We are focused on building a differentiated portfolio of transformational medicines for patients with serious and life-threatening diseases. There are a number of areas of focus across disease areas, drug platforms and technologies that we are interested in bringing together with our expertise to help speed medicines to patients.

      Existing Partnerships

      In order to develop innovative medicines, we collaborate with top tier organizations and research institutes around the world.

      Common Cold

      Working to #HackCancer

      Bristol-Myers Squibb Joins Parker Institute and Cancer Research Institute to Accelerate I-O Research

      Gut Instinct

      The Gut Microbiome and cancer treatment

      Contact us about partnering

      Start the partnership process. Please send NON-CONFIDENTIAL information about your opportunity to one of the individuals below based on your area of interest:

      Oncology:?BD-OncSnE@BMS.com
      Cardiovascular, Fibrosis and Immunoscience:?BD-CFISnE@BMS.com
      Discovery Technology:?BD-TechTrans@BMS.com
      PDx and Biomarker:?BD-PDxBiomarkers@bms.com

      日本最新免费一区